COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE plus DOCETAXEL VS GEMCITABINE plus DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE

被引：0
|
作者：
Tenorio, C. [1 ]
Vargas, J. [2 ]
Martinez, J. [3 ]
机构：
[1] Inst Nacl Cancerol, Mexico City, DF, Mexico
[2] Econopharma Consulting SA CV, Mexico City, DF, Mexico
[3] Econopharma, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74330-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A271 / A271
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China
    Zheng, Zhiwei
    Song, Xiaobing
    Qiu, Guodong
    Xu, Siqi
    Cai, Hongfu
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (03) : 433 - 440
  • [42] Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
    Bonneterre, J
    Roché, H
    Monnier, A
    Guastalla, JP
    Namer, M
    Fargeot, P
    Assadourian, S
    BRITISH JOURNAL OF CANCER, 2002, 87 (11) : 1210 - 1215
  • [43] Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
    J Bonneterre
    H Roché
    A Monnier
    J P Guastalla
    M Namer
    P Fargeot
    S Assadourian
    British Journal of Cancer, 2002, 87 : 1210 - 1215
  • [44] Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
    Reed, Shelby D.
    Li, Yanhong
    Anstrom, Kevin J.
    Schulman, Kevin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) : 2185 - 2191
  • [45] Population based cost-effectiveness analysis of combination capecitabine and docetaxel (DC) versus single agent docetaxel (D) in the treatment of metastatic breast cancer (MBC) following an anthracycline regimen
    Taylor, SM
    Barnett, J
    Chia, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S67 - S67
  • [46] Phase II study cisplatin plus gemcitabine (Gemzar) in antracycline, docetaxel and capecitabine-refractory metastatic breast cancer
    Semiglazova, Tatiana
    Filatova, Larisa
    ANNALS OF ONCOLOGY, 2004, 15 : 43 - 43
  • [47] Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase Ill study (J021095)
    Sato, N.
    Yamamoto, D.
    Rai, Y.
    Iwase, H.
    Saito, M.
    Iwata, H.
    Masuda, N.
    Oura, S.
    Watanabe, J.
    Kuroi, K.
    CANCER RESEARCH, 2012, 72
  • [48] Docetaxel plus cisplatin as salvage therapy for patients with metastatic breast cancer resistant to previous anthracycline treatment
    Park, Se Hoon
    Cho, Eun Kyung
    Bang, Soo Mee
    Shin, Dong Bok
    Lee, Jae Hoon
    Lee, Young Don
    ANNALS OF ONCOLOGY, 2004, 15 : 41 - 41
  • [49] A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
    Lee, Keun-Wook
    Kim, Bum Jun
    Kim, Mi-Jung
    Han, Hye Sook
    Kim, Jin Won
    Park, Young Lee
    Park, Sook Ryun
    CANCER RESEARCH AND TREATMENT, 2017, 49 (03): : 706 - 716
  • [50] A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine
    Kim, B.
    Lee, K. W.
    Kim, M. J.
    Han, H. S.
    Park, Y. L.
    Park, S. R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S432 - S432
12345